Strategic acquisition strengthens InSphero’s presence in the United States and expands advanced imaging and phenotypic analysis capabilities for drug discovery and safety testing

Mabylon AG, a leader in human-derived, half-life extended multi-specific antibodies, today reported positive Phase IA clinical trial data demonstrating a favorable safety profile of its lead candidate MY006. Safety Monitoring Committee (SMC) recommended initiation of Part B of the peanut allergy trial in patients. Funding secured for follow-on tree pollen program MY010. The multi-specific antibody

Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE attacks remains on-track in 1H2026 Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Cash and cash equival